SG10201900536TA - Piperidine derivatives as orexin receptor antagonist - Google Patents
Piperidine derivatives as orexin receptor antagonistInfo
- Publication number
- SG10201900536TA SG10201900536TA SG10201900536TA SG10201900536TA SG10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA SG 10201900536T A SG10201900536T A SG 10201900536TA
- Authority
- SG
- Singapore
- Prior art keywords
- piperidine derivatives
- orexin receptor
- receptor antagonist
- hypersomnia
- obsessive
- Prior art date
Links
- 229940123730 Orexin receptor antagonist Drugs 0.000 title abstract 3
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000014679 binge eating disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010020765 hypersomnia Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONIST The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, hypersomnia, anxiety, obsessive-compulsive disorder, panic attack, nicotine addiction, or binge eating disorder. 10 (No suitable figure)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410081220 | 2014-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201900536TA true SG10201900536TA (en) | 2019-02-27 |
Family
ID=54054589
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201900536TA SG10201900536TA (en) | 2014-03-06 | 2015-02-27 | Piperidine derivatives as orexin receptor antagonist |
SG11201607183PA SG11201607183PA (en) | 2014-03-06 | 2015-02-27 | Piperidine derivatives as orexin receptor antagonist |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607183PA SG11201607183PA (en) | 2014-03-06 | 2015-02-27 | Piperidine derivatives as orexin receptor antagonist |
Country Status (16)
Country | Link |
---|---|
US (1) | US10100047B2 (en) |
EP (1) | EP3115362B1 (en) |
JP (1) | JP6262885B2 (en) |
KR (1) | KR101920472B1 (en) |
CN (1) | CN106414439B (en) |
AU (1) | AU2015226679B2 (en) |
CA (1) | CA2941663C (en) |
CL (1) | CL2016002240A1 (en) |
IL (1) | IL247584A0 (en) |
MX (1) | MX2016011549A (en) |
NZ (1) | NZ723671A (en) |
PE (1) | PE20170184A1 (en) |
RU (1) | RU2669701C2 (en) |
SG (2) | SG10201900536TA (en) |
WO (1) | WO2015131773A1 (en) |
ZA (1) | ZA201606141B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105073728A (en) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (en) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
DK3336088T3 (en) * | 2015-08-14 | 2021-06-28 | Shanghai Haiyan Pharmaceutical Tech Co Ltd | Crystal form of orexin receptor antagonist compound, and method of making and using the same |
EP3380475A4 (en) | 2015-11-23 | 2019-07-03 | Sunshine Lake Pharma Co., Ltd. | OCTAHYDROPYRROLO [3, 4-c |
JP6609060B2 (en) | 2016-02-04 | 2019-11-20 | 武田薬品工業株式会社 | Substituted piperidine compounds and uses thereof |
US20230149402A1 (en) * | 2020-04-17 | 2023-05-18 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Solid pharmaceutical preparation, preparation method therefor and use thereof |
CN112480107B (en) * | 2020-11-30 | 2022-08-16 | 上海海雁医药科技有限公司 | Substituted azabicyclooctane compounds, intermediates therefor and processes for their preparation |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1641801B9 (en) * | 2003-05-13 | 2009-02-25 | Schering Corporation | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
US20090247499A1 (en) * | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
EP2150114A4 (en) * | 2007-05-18 | 2012-01-18 | Merck Sharp & Dohme | Oxo bridged diazepan orexin receptor antagonists |
CA2687230A1 (en) * | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
ES2379744T3 (en) * | 2007-05-23 | 2012-05-03 | Merck Sharp & Dohme Corp. | Pyridyl-piperidine antagonists of orexin receptors |
AU2009211724B2 (en) * | 2008-02-06 | 2013-05-16 | Msd K.K. | 3-substituted sulfonyl piperazine derivative |
JP2011512400A (en) * | 2008-02-21 | 2011-04-21 | アクテリオン ファーマシューティカルズ リミテッド | 2-Aza-bicyclo [2.2.1] heptane derivatives |
JP2012506378A (en) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,3-disubstituted phenylcarboxamide orexin receptor antagonist |
AU2009307915A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
CA2739919A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
US8669272B2 (en) * | 2008-10-21 | 2014-03-11 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
US9365564B2 (en) * | 2010-04-29 | 2016-06-14 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 |
JP5889895B2 (en) * | 2010-07-29 | 2016-03-22 | ライジェル ファーマシューティカルズ, インコーポレイテッド | AMPK activated heterocyclic compounds and methods of use thereof |
US20140228377A1 (en) * | 2011-07-05 | 2014-08-14 | Taisho Pharmaceutical Co., Ltd. | Methylpiperidine derivative |
AR088352A1 (en) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
EP2752410B1 (en) * | 2011-10-25 | 2016-08-31 | Shionogi & Co., Ltd. | Heterocycle derivative having pgd2 receptor antagonist activity |
JOP20130213B1 (en) * | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | 5-ht3 receptor antagonists |
US9730940B2 (en) * | 2012-11-16 | 2017-08-15 | Merck Sharp & Dohme | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
TWI621618B (en) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | Substituted 2-azabicycles and their use as orexin receptor modulators |
TW201444849A (en) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | Substituted 7-azabicycles and their use as orexin receptor modulators |
-
2015
- 2015-02-27 SG SG10201900536TA patent/SG10201900536TA/en unknown
- 2015-02-27 US US15/123,014 patent/US10100047B2/en active Active
- 2015-02-27 KR KR1020167027668A patent/KR101920472B1/en active IP Right Grant
- 2015-02-27 EP EP15758792.4A patent/EP3115362B1/en active Active
- 2015-02-27 WO PCT/CN2015/073330 patent/WO2015131773A1/en active Application Filing
- 2015-02-27 CA CA2941663A patent/CA2941663C/en active Active
- 2015-02-27 AU AU2015226679A patent/AU2015226679B2/en active Active
- 2015-02-27 NZ NZ723671A patent/NZ723671A/en unknown
- 2015-02-27 SG SG11201607183PA patent/SG11201607183PA/en unknown
- 2015-02-27 CN CN201580012396.4A patent/CN106414439B/en active Active
- 2015-02-27 JP JP2016572879A patent/JP6262885B2/en active Active
- 2015-02-27 PE PE2016001578A patent/PE20170184A1/en not_active Application Discontinuation
- 2015-02-27 RU RU2016130937A patent/RU2669701C2/en active
- 2015-02-27 MX MX2016011549A patent/MX2016011549A/en unknown
-
2016
- 2016-08-31 IL IL247584A patent/IL247584A0/en unknown
- 2016-09-05 ZA ZA2016/06141A patent/ZA201606141B/en unknown
- 2016-09-06 CL CL2016002240A patent/CL2016002240A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2669701C2 (en) | 2018-10-15 |
CA2941663C (en) | 2020-02-18 |
WO2015131773A1 (en) | 2015-09-11 |
ZA201606141B (en) | 2017-05-31 |
KR20160143668A (en) | 2016-12-14 |
RU2016130937A (en) | 2018-04-09 |
EP3115362A4 (en) | 2017-08-16 |
US20170233385A1 (en) | 2017-08-17 |
CN106414439A (en) | 2017-02-15 |
PE20170184A1 (en) | 2017-04-07 |
JP6262885B2 (en) | 2018-01-17 |
CN106414439B (en) | 2017-12-08 |
CL2016002240A1 (en) | 2017-02-17 |
US10100047B2 (en) | 2018-10-16 |
EP3115362B1 (en) | 2019-06-12 |
SG11201607183PA (en) | 2016-10-28 |
MX2016011549A (en) | 2017-05-08 |
CA2941663A1 (en) | 2015-09-11 |
EP3115362A1 (en) | 2017-01-11 |
JP2017507185A (en) | 2017-03-16 |
NZ723671A (en) | 2017-05-26 |
AU2015226679B2 (en) | 2017-05-25 |
AU2015226679A1 (en) | 2016-09-15 |
KR101920472B1 (en) | 2019-02-08 |
IL247584A0 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201900536TA (en) | Piperidine derivatives as orexin receptor antagonist | |
PH12018501235A1 (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | |
PH12019500131A1 (en) | Substituted diazahetero-bicyclic compounds and their use | |
PH12014501595A1 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
MA32975B1 (en) | ANTAGONISTS OF C5AR | |
IL266301A (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
IL268928B1 (en) | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone and their use | |
PH12016500065A1 (en) | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof | |
WO2014120936A3 (en) | Treatments for depression and other diseases with a low dose agent | |
CL2014003607A1 (en) | Compounds derived from benzodioxol, acetylcholinesterase inhibitors; Preparation method; intermediary compounds; pharmaceutical composition; and use in the prevention or treatment of Alzheimer's disease. | |
DK2413933T4 (en) | 2,4,6-Trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl] -benzamide for the treatment of migraine by oral or intravenous administration | |
MX371102B (en) | New benzimidazole derivatives as antihistamine agents. | |
PH12014502351A1 (en) | Methods of producing anamorelin hydrochloride having controlled chloride content | |
SA519410097B1 (en) | Tetrahydroquinoline derivatives as p2x7 receptor antagonists | |
TN2014000532A1 (en) | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
MX2016007652A (en) | Pharmaceutical dosage forms. | |
PH12017501736A1 (en) | Indole derivatives | |
MX2017017155A (en) | Thromboxane receptor antagonists in aerd/asthma. | |
Shahbazi | The New Frontier of Religion and Science Religious Experience, Neuroscience and the Transcendent | |
CN302567684S (en) | Upper rail for hanging door |